Cardiovascular disease in the antiphospholipid syndrome

Lupus

Volumn 23, Issue 12, 2014, Pages 1288-1291

  Amaya Amaya, Jenny ^a   Rojas Villarraga, Adriana ^a   Anaya, Juan Manuel ^a  

^a UNIVERSIDAD DEL ROSARIO   (Colombia)

Author keywords

antiphospholipid syndrome; Cardiovascular disease; novel risk factors; traditional risk factors

Indexed keywords

HIGH DENSITY LIPOPROTEIN; LUPUS ANTICOAGULANT; BETA2 GLYCOPROTEIN 1;

ANTICOAGULANT THERAPY; ANTIPHOSPHOLIPID SYNDROME; BLOOD VESSEL INJURY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CONFERENCE PAPER; CONGESTIVE CARDIOMYOPATHY; EARLY DIAGNOSIS; FOLLOW UP; HEART INFARCTION; HUMAN; HYPERTRIGLYCERIDEMIA; LIFESTYLE MODIFICATION; LUNG EMBOLISM; PREVALENCE; PULMONARY HYPERTENSION; THROMBOTIC THROMBOCYTOPENIC PURPURA; CARDIOVASCULAR DISEASES; COMPLICATION; PHYSIOLOGY; RISK FACTOR;

ANTIPHOSPHOLIPID SYNDROME; BETA 2-GLYCOPROTEIN I; CARDIOVASCULAR DISEASES; HUMANS; RISK FACTORS;

EID: 84908690021     PISSN: 09612033     EISSN: 14770962     Source Type: Journal    
DOI: 10.1177/0961203314540015     Document Type: Conference Paper

References (14)

1. Perez-Sanchez C, Barbarroja N, Messineo S, et al. Gene profiling reveals specific molecular pathways in the pathogenesis of atherosclerosis and cardiovascular disease in antiphospholipid syndrome, systemic lupus erythematosus and antiphospholipid syndrome with lupus. Ann Rheum Dis. Epub ahead of print 11 March 2014.
2. Shoenfeld Y, Gerli R, Doria A, et al. Accelerated atherosclerosis in autoimmune rheumatic diseases. Circulation. 2005 ; 112: 3337-3347
3. Amaya-Amaya J, Sarmiento-Monroy JC, Rojas-Villarraga A Autoimmunity: From bench to bedside. Anaya JM Shoenfeld Y Rojas-Villarraga A Levy RA Cervera R, ed. Bogotá, Colombia: Universidad del Rosario ; 2013: 653-682.
4. Giannakopoulos B, Krilis SA, Giannakopoulos BK. The pathogenesis of the antiphospholipid syndrome. N Engl J Med. 2013 ; 368: 1033-1044
5. Shortell CK, Ouriel K, Green RM, Condemi JJ, DeWeese JA. Vascular disease in the antiphospholipid syndrome: A comparison with the patient population with atherosclerosis. J Vasc Surg. 1992 ; 15: 158-165
6. Vaarala O, Mänttäri M, Manninen V, et al. Anti-cardiolipin antibodies and risk of myocardial infarction in a prospective cohort of middle-aged men. Circulation. 1995 ; 91: 23-27
7. Comarmond C, Cacoub P. Antiphospholipid syndrome: From pathogenesis to novel immunomodulatory therapies. Autoimmun Rev. 2013 ; 12: 752-757
8. Vlachoyiannopoulos PG, Samarkos M. Peripheral vascular disease in antiphospholipid syndrome. Thromb Res. 2004 ; 114: 509-519
9. Cervera R. Coronary and valvular syndromes and antiphospholipid antibodies. Thromb Res. 2004 ; 114: 501-507
10. Medina G, Gutiérrez-Moreno AL, Vera-Lastra O, Saavedra MA, Jara LJ. Prevalence of metabolic syndrome in primary antiphospholipid syndrome patients. Autoimmun Rev. 2011 ; 10: 214-217
11. Belizna CC, Richard V, Thuillez C, Lévesque H, Shoenfeld Y. Insights into atherosclerosis therapy in antiphospholipid syndrome. Autoimmun Rev. 2007 ; 7: 46-51
12. Veres K, Lakos G, Kerényi A, et al. Antiphospholipid antibodies in acute coronary syndrome. Lupus. 2004 ; 13: 423-427
13. Soltész P, Veres K, Lakos G, Kiss E, Muszbek L, Szegedi G. Evaluation of clinical and laboratory features of antiphospholipid syndrome: A retrospective study of 637 patients. Lupus. 2003 ; 12: 302-307
14. Erkan D, Aguiar CL, Andrade D, et al. 14th International Congress on Antiphospholipid Antibodies: Task force report on antiphospholipid syndrome treatment trends. Autoimmun Rev. 2014 ; 13: 685-696